文献速递心境障碍

经颅直流电刺激辅助治疗双相抑郁:随机临床试验

Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

这项随机假对照双盲试验在59例双相障碍抑郁发作成人中评估了经颅直流电刺激(tDCS)辅助治疗的疗效与安全性。第6周时,活性tDCS组HDRS-17改善显著优于假刺激组,累积应答率更高,但缓解率差异无统计学意义;不良事件总体相似,仅局部皮肤发红在活性组更常见。

要点

  • tDCS辅助治疗双相抑郁在第6周HDRS-17改善上优于假刺激。
  • 累积应答率活性组67.6%高于假刺激组30.4%,但缓解率差异无统计学意义。
  • 不良事件总体与假刺激相似,活性组局部皮肤发红更常见。

核心结论

  • 在这项小样本试验中,tDCS是双相抑郁有效、安全且耐受性良好的辅助干预。
  • 后续需在更大样本中进一步验证tDCS的疗效。

研究设计与样本

  • 随机、假对照、双盲试验(BETTER),2014年7月1日至2016年3月30日在单中心门诊学术机构开展。
  • 纳入59例I型或II型双相障碍处于抑郁发作的成人,接受稳定药物治疗且HDRS-17评分高于17。
  • 分析采用意向性治疗样本。

主要发现

  • 意向性治疗分析中,活性tDCS组HDRS-17改善显著优于假刺激组(βint=-1.68;需治疗人数5.8;95%CI 3.3-25.8;P=.01)。
  • 累积应答率活性组67.6%高于假刺激组30.4%(需治疗人数2.69;95%CI 1.84-4.99;P=.01)。
  • 缓解率活性组37.4%与假刺激组19.1%差异无统计学意义(需治疗人数5.46;95%CI 3.38-14.2;P=.18)。
  • 不良事件包括治疗诱发的情绪转相在两组间相似,活性组局部皮肤发红更常见(54% vs 19%;P=.01)。

关键数值与推荐

  • 主要结局为第6周HDRS-17评分变化。
  • 共59例患者(40例[68%]女性),平均(SD)年龄45.9(12)岁;36例(61%)为双相I型,23例(39%)为双相II型;52例完成试验。

临床怎么用

  • 对于稳定药物治疗下HDRS-17高于17的双相抑郁成人,tDCS可作为辅助治疗选择,但需注意局部皮肤发红。
  • tDCS对累积应答率有优势,但缓解率未显示显著差异,临床决策需结合个体情况。

局限性

  • 样本量小(59例),需更大样本试验验证疗效。
  • 单中心门诊学术机构开展,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: More effective, tolerable interventions for bipolar depression treatment are needed. Transcranial direct current stimulation (tDCS) is a novel therapeutic modality with few severe adverse events that showed promising results for unipolar depression. OBJECTIVE: To determine the efficacy and safety of tDCS as an add-on treatment for bipolar depression. DESIGN, SETTING, AND PARTICIPANTS: A randomized, sham-controlled, double-blind trial (the Bipolar Depression Electrical Treatment Trial [BETTER]) was conducted from July 1, 2014, to March 30, 2016, at an outpatient, single-center academic setting. Participants included 59 adults with type I or II bipolar disorder in a major depressive episode and receiving a stable pharmacologic regimen with 17-item Hamilton Depression Rating Scale (HDRS-17) scores higher than 17. Data were analyzed in the intention-to-treat sample. INTERVENTIONS: Ten daily 30-minute, 2-mA, anodal-left and cathodal-right prefrontal sessions of active or sham tDCS on weekdays and then 1 session every fortnight until week 6. MAIN OUTCOMES AND MEASURES: Change in HDRS-17 scores at week 6. RESULTS: Fifty-nine patients (40 [68%] women), with a mean (SD) age of 45.9 (12) years participated; 36 (61%) with bipolar I and 23 (39%) with bipolar II disorder were randomized and 52 finished the trial. In the intention-to-treat analysis, patients in the active tDCS condition showed significantly superior improvement compared with those receiving sham (βint = -1.68; number needed to treat, 5.8; 95% CI, 3.3-25.8; P = .01). Cumulative response rates were higher in the active vs sham groups (67.6% vs 30.4%; number needed to treat, 2.69; 95% CI, 1.84-4.99; P = .01), but not remission rates (37.4% vs 19.1%; number needed to treat, 5.46; 95% CI, 3.38-14.2; P = .18). Adverse events, including treatment-emergent affective switches, were similar between groups, except for localized skin redness that was higher in the active group (54% vs 19%; P = .01). CONCLUSIONS AND RELEVANCE: In this trial, tDCS was an effective, safe, and tolerable add-on intervention for this small bipolar depression sample. Further trials should examine tDCS efficacy in a larger sample. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02152878.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sampaio-Junior B, Tortella G, Borrione L, et al. Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29282470. doi:10.1001/jamapsychiatry.2017.4040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。